Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01370265 · ClinicalTrials.gov registry record · NA
Myocardial Blood Flow by PET and N-13 Ammonia During Regadenoson vs Adenosine Stress
A NA study, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 12
- Enrollment target
NCT01370265: Completed NA study, sponsored by Mayo Clinic.
NCT01370265 is a NA study that has completed, run by Mayo Clinic. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01370265, a NA study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
Study Summary
Blockage of the heart arteries (coronary artery disease) can lead to angina (chest pain), heart attacks, heart failure, and/or death. Positron emission tomography (PET) stress myocardial perfusion imaging (MPI) is a powerful tool to help identify blockages in the coronary arteries. During the PET MPI test, a drug is given to mimic the effects of exercise on the heart. The study was done to measure blood flow to the heart using two similar drugs approved to mimic the effects of exercise on the heart in people during a heart stress test. The first drug, called adenosine, has been approved for this use for several decades. The second drug, called regadenoson, was approved in 2008. The investigators were looking at whether the increase in blood flow to the heart with the newer drug (regadenoson) was similar to the increase in blood flow with the older drug (adenosine). This information is important for the use of these drugs in patients and for interpreting the blood flow values.
Interventions
- DRUG Regadenoson
- DRUG Adenosine
- DRUG N-13 ammonia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2011-02 |
| Est. Completion | 2012-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01370265
The ClinicalTrials.gov registry entry for NCT01370265 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Regadenoson is the first listed.
NCT01370265 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01370265 about?
NCT01370265 is a clinical study titled "Myocardial Blood Flow by PET and N-13 Ammonia During Regadenoson vs Adenosine Stress". Blockage of the heart arteries (coronary artery disease) can lead to angina (chest pain), heart attacks, heart failure, and/or death. Positron emission tomography (PET) stress myocardial perfusion imaging (MPI) is a powerful tool to help identify blockages in the coronary arteries. During the PET MP...
What is the current status of trial NCT01370265?
This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2011-02. Estimated completion is 2012-06.
What interventions are being tested in trial NCT01370265?
The interventions under investigation include: Regadenoson (DRUG), Adenosine (DRUG), N-13 ammonia (DRUG).
Who is sponsoring clinical trial NCT01370265?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.